MacroGenics (MGNX) Reports Q2 Loss, Tops Revenue Estimates

Group 1 - MacroGenics reported a quarterly loss of $0.57 per share, which was better than the Zacks Consensus Estimate of a loss of $0.59, and an improvement from a loss of $0.89 per share a year ago, resulting in an earnings surprise of +3.39% [1] - The company posted revenues of $22.24 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 4.73%, and showing significant growth from year-ago revenues of $10.8 million [2] - MacroGenics shares have declined approximately 48.9% since the beginning of the year, contrasting with a 10% gain in the S&P 500 [3] Group 2 - The earnings outlook for MacroGenics is mixed, with the current consensus EPS estimate for the coming quarter at -$0.40 on revenues of $26.77 million, and -$2.04 on revenues of $92.12 million for the current fiscal year [7] - The Zacks Industry Rank indicates that the Medical - Products sector is currently in the bottom 39% of over 250 Zacks industries, suggesting potential challenges for stocks in this category [8] - Ayr Wellness Inc., another company in the same industry, is expected to report a quarterly loss of $0.29 per share, reflecting a year-over-year change of +14.7%, with revenues projected at $111.05 million, down 5.3% from the previous year [9]